Sanne is a Partner in the Life Sciences team at Oxford Science Enterprises. At OSE she is focused on the sourcing and structuring of new spinout opportunities from the University of Oxford, as well as supporting the existing Life Sciences portfolio.
Prior to OSE, she was an investment manager at specialist transatlantic investor Gilde Healthcare, where she focused on European biotech investments, such as Tagworks Pharmaceuticals, ADCendo, Draupnir Bio and Calypso Biotech. Prior to Gilde, Sanne was at Anterra Capital, a transatlantic Food and Ag Tech VC firm, at which she focused on the creation and backing of biotech companies, such as Enko Chem and Caribou Biosciences. Sanne began her career at M Ventures, the strategic corporate VC fund of Merck KGaA, focused on healthcare.
She holds a BSc in Biochemistry from Leiden University with a minor in Neurology, and MSc in Biochemical Engineering from Delft University of Technology, the Netherlands, graduating cum laude. Next to Sitryx, she serves as a Director on the boards of OSE’s portfolio companies Orfonyx Bio and Match Bio.
